Active ingredientLemborexantCat. No. P-L031-001CAS 1369764-02-2Family · Pharmaceutical analytical standards
Lemborexant
A dual orexin receptor antagonist, blocking the action of the neuropeptides that keep us awake; approved in the United States in December 2019 for insomnia in adults. This family brings together the active ingredient and other impurities.
Did you know?Orexins were discovered in 1998 and named after the Greek orexis, appetite, because they seemed to stimulate hunger: only later was their key role in wakefulness and narcolepsy understood.
Go to the active ingredient →Active ingredientLemborexantCat. No. P-L031-001CAS 1369764-02-2
Impurityent-Lemborexant (1S,2R)Cat. No. P-L031-002
ImpurityLemborexant Deschloro Impurity (1R,2S)Cat. No. P-L031-003
ImpurityLemborexant Impurity 1Cat. No. P-L031-004CAS 528587-70-4
ImpurityLemborexant Impurity 2Cat. No. P-L031-005CAS 1369769-35-6
ImpurityLemborexant Impurity 3Cat. No. P-L031-006
ImpurityLemborexant Impurity 4Cat. No. P-L031-007CAS 1369767-20-3
ImpurityLemborexant Impurity 5Cat. No. P-L031-008CAS 1450904-92-3
ImpurityLemborexant Impurity 6Cat. No. P-L031-009
ImpurityLemborexant Impurity 7Cat. No. P-L031-010
ImpurityLemborexant Impurity 8Cat. No. P-L031-011CAS 2541020-19-1
ImpurityLemborexant Impurity 9Cat. No. P-L031-012
ImpurityLemborexant Impurity 10Cat. No. P-L031-013
ImpurityLemborexant N1-OxideCat. No. P-L031-014CAS 1369765-94-5
ImpurityLemborexant N2-OxideCat. No. P-L031-015CAS 1369765-95-6No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.